{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/incontinence-urinary-in-women/prescribing-information/desmopressin/","result":{"pageContext":{"chapter":{"id":"c57e795e-2c4a-5f04-83ae-289890ef29ea","slug":"desmopressin","fullItemName":"Desmopressin","depth":2,"htmlHeader":"<!-- begin field c305d954-5d47-4cc2-9c62-c2d4c85f5e39 --><h2>Desmopressin</h2><!-- end field c305d954-5d47-4cc2-9c62-c2d4c85f5e39 -->","summary":"","htmlStringContent":"<!-- begin item aba92ab4-2c6b-4660-9e2a-9ea08373c9b2 --><!-- begin field d398d7d1-4db2-45dc-bf00-a650ff6cb55e --><ul><li>The use of desmopressin for the treatment of nocturnal polyuria is off label [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2012</a>].</li></ul><!-- end field d398d7d1-4db2-45dc-bf00-a650ff6cb55e --><!-- end item aba92ab4-2c6b-4660-9e2a-9ea08373c9b2 -->","topic":{"id":"c16535c5-1fa2-5d4a-a89f-9863872fca0e","topicId":"9e411d60-4060-4d95-8511-0998688cea47","topicName":"Incontinence - urinary, in women","slug":"incontinence-urinary-in-women","lastRevised":"Last revised in October 2019","chapters":[{"id":"592d340e-2c89-5e8e-9781-8398ef51af2c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"93b3be44-57e0-59a2-b936-4b447f0b2961","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c15069c4-b8dd-5092-9861-e20a636b9367","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3dc5fefe-1cf0-54d7-92d3-e1c0c60c6fb9","slug":"changes","fullItemName":"Changes"},{"id":"fb9741e6-b4f0-5ec2-ada2-a14af327feed","slug":"update","fullItemName":"Update"}]},{"id":"1ae974b5-487a-5fdf-88b5-6d9ed1e83525","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"399a4681-e92c-5e84-a738-fded957e135f","slug":"goals","fullItemName":"Goals"},{"id":"6507910a-37cb-51a9-8d3d-b69725293a87","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9cd9dcb7-4d7b-5d3b-aa75-6fb40bf5928b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f79e3765-8adb-5e3f-b68f-48aa4ddeb34b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e1ab1bca-96c7-5187-894e-1e1fe32f92d6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"97c63b91-f53e-5694-b807-0899dd34d53a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0c2e43fc-1afb-59f4-8819-0ff5edc09eeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3ab1ad04-1d9d-52bc-b4c9-ad0787598df3","slug":"definition","fullItemName":"Definition"},{"id":"a9c53f9f-2962-5eb2-8cae-91fc90a5a1f4","slug":"causes-contributing-factors","fullItemName":"Causes and contributing factors"},{"id":"4bbda54d-1a4f-591c-8463-082fcdf61d7c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e79a0901-9992-5f45-8cf5-c15ce06b5deb","slug":"complications","fullItemName":"Complications"},{"id":"b70db9b0-ddc3-5b42-888e-7171189f4ee5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a84e9562-3c9c-5c5e-8832-06e65a89aa2f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"49f48003-2f49-51d5-acfe-7ba0fcff8fae","slug":"assessment-overview","fullItemName":"Assessment overview"},{"id":"060afa31-1619-5a1a-a7e5-bcb583129aca","slug":"assessing-the-type-of-urinary-incontinence","fullItemName":"Assessing the type of urinary incontinence"},{"id":"9897aa86-8c09-5550-8496-da8cb12787bf","slug":"assessing-for-underlying-causes-contributing-factors","fullItemName":"Assessing for underlying causes and contributing factors"},{"id":"49079af0-34b2-5cab-9135-40f57ee1eea4","slug":"assessing-for-complications","fullItemName":"Assessing for complications"},{"id":"c9c5f464-0433-5027-a22c-8d2b8fb239bd","slug":"assessing-the-severity-of-urinary-incontinence","fullItemName":"Assessing the severity of urinary incontinence"}]},{"id":"a7454b90-f574-597a-b3ce-8f0b3967e058","fullItemName":"Management","slug":"management","subChapters":[{"id":"26043de5-bad9-57d7-abad-98942e3ed62c","slug":"managing-stress-incontinence","fullItemName":"Scenario: Managing stress incontinence"},{"id":"280a972f-ec97-53b4-ab56-b67df1df40d3","slug":"managing-urgency-incontinence","fullItemName":"Scenario: Managing urgency incontinence"},{"id":"dff61990-c7a9-5600-b15a-e9098f480b65","slug":"managing-mixed-urinary-incontinence","fullItemName":"Scenario: Managing mixed urinary incontinence"},{"id":"4e21298e-b75d-5104-9b4b-a9817cb8d9b6","slug":"managing-overflow-urinary-incontinence","fullItemName":"Scenario: Managing overflow urinary incontinence"},{"id":"d5ace44e-cc5a-5618-bb48-24058af84ec8","slug":"managing-a-urogenital-fistula","fullItemName":"Scenario: Managing a urogenital fistula"}]},{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3d2d4594-7f5e-5ad4-9537-22965cd3859f","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"c57e795e-2c4a-5f04-83ae-289890ef29ea","slug":"desmopressin","fullItemName":"Desmopressin"},{"id":"2bf52d86-2720-51b1-9411-89ebb7ff9b07","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"7f2a8cea-ac55-5ac4-a58a-52dbe5d19228","slug":"intravaginal-oestrogen","fullItemName":"Intravaginal oestrogen"},{"id":"2e7111be-d25f-52ec-9f6b-2aaea7583699","slug":"mirabegron","fullItemName":"Mirabegron"}]},{"id":"3ef95f2d-4da4-5002-9243-64779078fc11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bdb709b8-1321-594d-b446-51244a4b8f41","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ce87fd7-7343-5da1-b9a5-0035a5703c2c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3fe3b863-a1f0-5938-9f0d-bb718d670d28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"947b96f3-7dc6-5136-96f6-431519b4646a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"16662eed-08e1-5333-85c0-65d2e4722f09","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9c5908f0-10fa-5d1c-8762-8a682a1ee2c8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"532bc548-9f39-5742-9a38-cb92893a8407","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"bede0448-a312-5a7b-8be2-812c94438195","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field b11b0f75-676e-440b-b874-d11dd13d0342 --><h3>When should desmopressin be avoided?</h3><!-- end field b11b0f75-676e-440b-b874-d11dd13d0342 -->","summary":"","htmlStringContent":"<!-- begin item c09bd11f-7e6f-489a-bef8-4b2d78556eaf --><!-- begin field f17a9f62-abc1-4459-8b91-77bc2288e856 --><ul><li><strong>Do not prescribe desmopressin to people:</strong><ul><li>With cardiac insufficiency.</li><li>With a history of hyponatraemia.</li><li>With hypertension (controlled or uncontrolled).</li><li>Taking diuretics.</li><li>With psychogenic polydipsia or alcohol abuse.</li><li>Syndrome of inappropriate ADH secretion.</li></ul></li><li><strong>Where possible, avoid prescribing desmopressin</strong> for primary nocturnal enuresis and nocturia associated with multiple sclerosis<strong> </strong>in people aged over 65 years.</li><li><strong>Prescribe desmopressin with caution to people with:</strong><ul><li>Asthma.</li><li>Cardiovascular disease. </li><li>Cystic fibrosis.</li><li>Conditions characterized by fluid and/or electrolyte imbalance.</li><li>Epilepsy.</li><li>Hypertension (not indicated for nocturnal enuresis or nocturia). </li><li>Migraine.</li><li>Renal impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field f17a9f62-abc1-4459-8b91-77bc2288e856 --><!-- end item c09bd11f-7e6f-489a-bef8-4b2d78556eaf -->","subChapters":[]},{"id":"c45973a0-a4f7-5b3f-ac13-a8f4ab01a946","slug":"initiation-titration","fullItemName":"Initiation and titration","depth":3,"htmlHeader":"<!-- begin field 2614faae-f641-48e6-8c7c-6a0df7af640b --><h3>How should I start and titrate desmopressin?</h3><!-- end field 2614faae-f641-48e6-8c7c-6a0df7af640b -->","summary":"","htmlStringContent":"<!-- begin item 5d9bd9d8-72d2-498b-b166-69e87699bbe6 --><!-- begin field 362ca00e-79ef-4cef-8e1d-a7591f38d5c8 --><ul><li>Prescribe a starting dose of 200 micrograms of oral desmopressin at bedtime (off-label indication). </li><li>Limit fluid intake for 1 hour before to 8 hours after taking desmopressin. </li><li>Reassess the need for continued treatment after 3 months by withdrawing treatment for at least 1 week.</li><li>If needed, the dose can be increased to 400 micrograms at bedtime.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 362ca00e-79ef-4cef-8e1d-a7591f38d5c8 --><!-- end item 5d9bd9d8-72d2-498b-b166-69e87699bbe6 -->","subChapters":[]},{"id":"44c061d5-7d8b-57ff-9851-83510a023fdd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9cec61b8-5439-4ac8-b3d9-81fa9e55f0f3 --><h3>What are the key adverse effects of desmopressin, and how should I manage them?</h3><!-- end field 9cec61b8-5439-4ac8-b3d9-81fa9e55f0f3 -->","summary":"","htmlStringContent":"<!-- begin item 3ea07410-8761-4fd3-a0f7-a59071581ab1 --><!-- begin field 942708af-2ae0-4fe2-8bd4-ff3d2a6a12c8 --><ul><li><strong>Adverse effects of desmopressin include:</strong><ul><li>Fluid retention and hyponatraemia (especially if desmopressin treatment is given without concomitant reduction in fluid intake).</li><li>Headache.</li><li>Abdominal pain.</li><li>Nausea and vomiting.</li><li>Weight gain.</li><li>Convulsions (in serious cases).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 942708af-2ae0-4fe2-8bd4-ff3d2a6a12c8 --><!-- end item 3ea07410-8761-4fd3-a0f7-a59071581ab1 -->","subChapters":[]},{"id":"bf172e1b-c08e-5a54-9e13-0e80af74bccf","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 2d6438ca-8bfe-42ed-896e-5796b2983149 --><h3>What are the key drug interactions of desmopressin that I should be aware of?</h3><!-- end field 2d6438ca-8bfe-42ed-896e-5796b2983149 -->","summary":"","htmlStringContent":"<!-- begin item b975b4a3-64f1-454f-8598-4f1306829f35 --><!-- begin field d1717a02-a09b-4670-99c3-418cb600581b --><ul><li>There may be an increased risk of water retention and hyponatraemia if desmopressin is taken concurrently with certain drugs, including: ​​​​​​<ul><li>Carbamazepine.</li><li>Chlorpromazine.</li><li>Lamotrigine.</li><li>Loperamide (may increase desmopressin plasma concentrations).</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs).</li><li>Selective serotonin reuptake inhibitors (SSRIs).</li><li>Tricyclic antidepressants. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field d1717a02-a09b-4670-99c3-418cb600581b --><!-- end item b975b4a3-64f1-454f-8598-4f1306829f35 -->","subChapters":[]},{"id":"710599a6-dd78-513f-9e40-2944b79239c1","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field dbf26562-5dfb-4baf-9769-97e8d8e16953 --><h3>How should I monitor a person taking desmopressin?</h3><!-- end field dbf26562-5dfb-4baf-9769-97e8d8e16953 -->","summary":"","htmlStringContent":"<!-- begin item 228f6501-6a4f-4a46-a117-1e059c3a50cc --><!-- begin field d34866ec-17b0-4e25-8b13-e951ad8c24b1 --><ul><li>Measure serum sodium levels 3 days after the first dose, and if hyponatraemia is suspected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">NICE, 2010</a>].<ul><li>If serum sodium level is below the normal range, stop desmopressin treatment.</li></ul></li><li>In nocturia, periodic checking of blood pressure and body weight is recommended to monitor for fluid overload [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]. </li></ul><!-- end field d34866ec-17b0-4e25-8b13-e951ad8c24b1 --><!-- end item 228f6501-6a4f-4a46-a117-1e059c3a50cc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}